Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study.

Across all three eosinophil risk categories, no statistically significant between-group differences were observed at either timepoint, with the exception of a nominally significant finding in the high-risk category (≥300 cells/μL) at both 6 and 12 months; as these counts fell below the TriNetX privacy threshold and were reported as rounded values, no conclusions regarding eosinophilia trajectory can be drawn from these data ( 32 ).

also in 7,732 other papers